Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.
BNT162b2
COVID-19
SARS-CoV-2
antibody response
mRNA vaccine
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
03 Oct 2021
03 Oct 2021
Historique:
received:
17
08
2021
revised:
17
09
2021
accepted:
24
09
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53-339.52) with a significant increase compared to baseline ( Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.
Sections du résumé
BACKGROUND
BACKGROUND
We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection.
METHODS
METHODS
An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay.
RESULTS
RESULTS
Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53-339.52) with a significant increase compared to baseline (
CONCLUSIONS
CONCLUSIONS
Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.
Identifiants
pubmed: 34696233
pii: vaccines9101125
doi: 10.3390/vaccines9101125
pmc: PMC8538824
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9705-9711
pubmed: 33015816
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Vaccine. 2018 Aug 28;36(36):5350-5357
pubmed: 28774561
Blood. 2011 Aug 4;118(5):1294-304
pubmed: 21562046
Clin Cancer Res. 2021 Sep 28;:
pubmed: 34583970
Arch Intern Med. 2008 Dec 8;168(22):2405-14
pubmed: 19064822
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):869-74
pubmed: 24367114
Vaccines (Basel). 2021 Jun 22;9(7):
pubmed: 34206312
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Vaccines (Basel). 2021 Jul 27;9(8):
pubmed: 34451950
Vaccines (Basel). 2021 Jul 01;9(7):
pubmed: 34358130
Vaccine. 2010 Nov 29;28(51):8077-84
pubmed: 20974306
Blood. 2011 Aug 4;118(5):1305-15
pubmed: 21543762
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Viral Immunol. 2018 Mar;31(2):195-203
pubmed: 29336703
PLoS One. 2015 Jun 24;10(6):e0131531
pubmed: 26107625
Clin Immunol. 2018 Aug;193:80-87
pubmed: 29425852
Vaccine. 2016 May 27;34(25):2834-40
pubmed: 27108193
J Infect. 2021 Aug;83(2):e4-e5
pubmed: 34214516
Front Immunol. 2019 Feb 27;10:180
pubmed: 30873150
EClinicalMedicine. 2021 Jun;36:100928
pubmed: 34109307